Total: $2,168.94M | ||||
Company |
Type Of Financing |
Number |
Amount Raised (M) |
Investors; Placement |
| | ||||
Aastrom |
Private placement of common stock |
N/A |
$9.5 |
Aastrom raised $9.5M through a private placement of common stock (7/10) |
Advanced |
Private placement of common stock |
1S and W |
$10 |
Advanced Magnetics raised $10M in the private placement of 1M shares; investors also will receive warrants to purchase 261,780 shares at $15.50 per share (7/3) |
AEterna |
Bought-deal financing |
4.5S |
C$35.6 |
AEterna raised US$26.2M by selling 4.5M shares to a syndicate of underwriters, which also received an option to purchase up to an additional 1M shares; the underwriters were RBC Capital Markets, National Bank Financial Inc., Paradigm Capital Inc., Desjardins Securities Inc. and Loewen, Ondaatje, McCutcheon Ltd. (7/8) |
Amylin |
Private placement of convertible senior notes |
N/A |
$25 |
Amylin raised another $25M in its private placement of $150M of senior notes through the exercise of the overallotment option (7/18) |
Avanir |
Private placement of common stock and warrants |
N/A |
$10 |
Avanir raised $10M through the placement of common stock to accredited investors, who also received a warrant to purchase one Class A common share for every five shares of stock purchased in the offering; ThinkEquity Partners LLC acted as the offering's placement agent (7/24) |
Avant |
Private placement of common stock and warrants |
4.4S and |
$10 |
Avant raised $10M in a financing; Rodman & Renshaw was placement agent (7/1) |
Biopure |
Private placement of common stock |
3.1S |
$17.2 |
Biopure raised $17.2M with the placement of 3.1M shares to a group of investors; ThinkEquity Partners LLC acted as the offering's placement agent (7/24) |
Celsion Corp. |
Private placement of common stock |
11.9S |
$5.1 |
Celsion raised $5.1M through the exercise of out- standing common stock purchase warrants, resulting in the issuance of about 11.9M shares (7/8) |
Chiron |
Private placement of convertible debentures |
N/A |
$450 |
Chiron raised about $450M by selling debentures to institutional buyers (7/25) |
Columbia |
Private placement of common stock |
2.2S |
$26.3 |
Columbia raised $26.3M through the placement of 2.2M shares with institutional investors (7/24) |
Cytogen |
Private placement of common stock and warrants |
1.2S and |
$10 |
Cytogen raised $10M in the private placement with institutional investors (7/11) |
DOR |
Private placement of common stock and warrants |
6.8S and |
$5.4 |
DOR raised $5.4M through the placement led by OrbiMed Advisors LLC; other investors were Perceptive Life Sciences Fund, Wexford Capital, Height Capital, Eagle Advisors and A.M. Pappas & Co.; the placement agent was Paramount Capital Inc. (7/21) |
DOV |
Private placement of stock and warrants |
1.4S and |
$15 |
DOV raised $15M in a private placement of stock and warrants to a group of funds managed by OrbiMed Advisors LLC (7/3) |
Durect |
Private placement of convertible notes |
N/A |
$10 |
The initial purchaser of $50M of Durect's 6.25% convertible notes due 2008 elected to exercise its option to purchase an additional $10M in notes (7/14) |
EpiTan |
Exercise of |
N/A |
A$2.5 |
EpiTan raised US$1.7M through the exercise of 8.3M options (7/1) |
Genetronics |
Private |
N/A |
$8.2 |
Genetronics raised about $8.2M in a Series A cumulative convertible preferred stock deal; it also could receive another $7.5M in a similar Series B deal; that money was placed in escrow to be released upon an undisclosed milestone (7/16) |
GTC Biothera- |
Private |
3.6S and |
$9.26 |
GTC Biotherapeutics raised $9.26M in the placement; it would raise a total of $12.2M if all warrants are exercised (7/31) |
Guilford |
Private |
N/A |
$9.3 |
Guilford raised another $9.3M in an offering to cover overallotments; that brings gross proceeds to $69.3M, with $60M being raised in June (7/30) |
Hemispherx |
Private |
N/A |
$5.43 |
Hemispherx raised $5.43M in the placement with investors (7/14) |
ICOS Corp. |
Private |
N/A |
$28.7 |
ICOS raised another $28.7M through the exercise of an option on the part of the initial purchasers of $250M of its 2% convertible subordinated notes (7/16) |
Incara |
Bridge loan |
N/A |
$3 |
Incara closed on a $3M bridge loan facility (7/29) |
Indevus |
Private |
N/A |
$60 |
Indevus raised $60M through the placement of notes to qualified institutional buyers (7/11) |
InSite Vision |
Secured loan interim financing |
N/A |
$0.4 |
InSite Vision received a $400,000 secured loan from an investor in an interim financing (7/15) |
Insmed Inc. |
Private |
4.44S |
$13.9 |
Insmed raised $13.9M in the placement with a group of institutional investors; Wells Fargo Securities LLC served as lead placement agent (7/11) |
Invitrogen |
Private |
N/A |
$325 |
Invitrogen raised $325M worth of notes sold to institutional buyers (7/29) |
Isotechnika |
Private |
6.5S |
$15 |
Isotechnika raised $15M in the placement; Banc of America Securities LLC served as lead placement agent, with Friedman, Billings, Ramsey & Co. Inc. acting as co-manager (7/18) |
Medarex |
Private |
N/A |
$125 |
Medarex raised $125M in an offering to institutional buyers (7/18) |
MedImmune |
Private |
N/A |
$500 |
MedImmune raised $500M in the private placement (7/10) |
Nabi Bio- |
Private |
5.5S |
$32.9 |
Nabi raised $32.9M in a private placement of 5.5M shares; Lehman Brothers Inc. was the placement agent (7/14) |
Nektar |
Private |
N/A |
$10 |
Nektar raised another $10M when buyers exercised their overallotment option, increasing the principal amount sold to $110M; $100M was raised in June (7/30) |
NexMed |
Private |
2.9S and |
$10.5 |
NexMed raised $10.5M through a private placement of about 2.9M shares; investors included The Tailwind Fund, MidSummer Capital and Viking Global Investors; investors also received warrants to purchase about 1M common shares (7/7); Nex-Med also entered an agreement for a $1.85M line of credit with GE Life Science and Technology Finance (7/30) |
Northfield |
Private |
1.9S |
$10.6 |
Northfield raised $10.6M by selling 1.9M shares to accredited investors; SG Cowen Securities Corp. acted as the placement agent (7/24) |
NPS Pharma- |
Private |
N/A |
$22 |
NPS raised an additional $22M for a total of $192M because the initial purchasers exercised their option to purchase additional notes (7/10) |
Paradigm |
Debt financing agreement |
N/A |
-- |
Paradigm gained access to $7.5M in an agreement with Silicon Valley Bank, including a $5M term loan and a $2.5M revolving line of credit (7/10) |
Pluristem Life |
Private |
N/A |
$1.3 |
Pluristem raised a total of $1.3M in a second round (7/29) |
Protein |
Private |
N/A |
$250 |
Protein Design Labs raised $250M through the sale of convertible subordinated notes (7/9) |
Proteome |
Private |
N/A |
£5.8 |
Proteome Sciences raised US$9.3M in a private placement with institutional investors (7/2**) |
Sonus Pharma- |
Private |
3.9S |
$13.1 |
Sonus raised $13.1M in a private placement of 3.9M shares to new and current institutional in- vestors (7/29) |
Syn-X |
Private |
N/A |
C$3 |
Syn-X raised US$2.2M in the private placement that was accompanied by about 1.5M common purchase share warrants (7/10) |
The Immune |
Exercise |
7W |
$9.4 |
Immune Response gained $9.4M through a voluntary exercise of more than 7M Class A warrants (7/11) |
Trinity |
Private |
N/A |
$20 |
Trinity Biotech raised $20M after completing a private placement of 3% convertible notes due 2007 to three institutional investors (7/11) |
Vasogen |
Private |
9.375S |
$37.5 |
Vasogen raised $37.5M in a private placement; investors were Quest Diagnostics, WPG Farber Fund, AIG Global Investment, China Development Industrial Bank, George Weiss Associates, Knott Partners, Oakmont Corp., Straus Asset Management, Sceptre Investment Counsel and AGF Management; Needham & Co. acted as placement agent (7/3) |
Viragen |
Private |
N/A |
$5.55 |
Viragen raised $5.55M in a financing with institutional stockholders (7/1) |
| | ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.